Catalent (NYSE:CTLT) stock is climbing higher on Monday after the company agreed to sell itself to Novo Nordisk (NYSE:NVO) parent Novo Holdings for $16.5 billion.The transaction will have Novo Holdings paying $63.50 per share in cash for CTLT stock. That represents a premium of 16.5% over the closing price for Catalent’s stock on Friday. It’s also a 47.5% premium to the 60-day volume-weighted average price of the shares.After the deal closes, Novo Holdings intends to sell three of Catalent’s 60 locations to ...

Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023.Novo Nordisk's parent company on Monday said it will acquire drug manufacturer Catalent in a $16.5 billion deal that could help boost the supply of the highly popular weight loss injection Wegovy and diabetes shot Ozempic. Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy. As part of the d ...

Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)’s controlling shareholder was to buy the firm for US$16.5 billion. Novo Holdings, which owns a majority stake in the weight-loss drug maker, unveiled the takeover on Monday, which includes assumed debt and, at US$63.50 a share, represents a 16.5% premium on Catalent’s Friday closing price. Novo Nordisk (NYSE:NVO), Europe’s largest company by market cap, will take control of t ...

Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it’s buying Catalent CTLT, +2.67% for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday’s close. The deal is a 39% premium to Catalent’s close before it announced a strategic review. Novo will sell three fill-finish sites to Novo Nordisk shortly after the deal closes. Catalent investor Elliott Investment Management said it supports the deal. ...

COPENHAGEN, Denmark & SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise val ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the second quarter of fiscal year 2024 ended December 31, 2023, before the market open on Friday, February 9, 2024. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on the same day. Catalent invites all interested parties to listen to the webcast and view a su ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced its targets to reduce greenhouse gas emissions (Scope 1 and 2) by 42% by 2030. The company also committed to engaging with its suppliers, of purchased goods and services, capital goods, and upstream transportation and distribution, such that 70% of their emissions will have reduction goals aligned with science-based targets by the end of ...

______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________ Catalent, Inc. (Exact name of registrant as specified in its charter) _____________________________ Delaware 20-8737688 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 14 Schoolhouse Road Somerset, New Jersey 08873 (Address of principal executive offices)_______ (Zip code) (732) 537-6200 Registrant's telepho ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 atalent CATALENT, INC. (Exact name of registrant as specified in its charter) | --- | --- | |------------------------------------------------- ...

Catalent, Inc. (NYSE:CTLT) Q1 2024 Earnings Call Transcript November 15, 2023 8:15 AM ET Paul Surdez - Vice President of Investor Relations Alessandro Maselli - President and Chief Executive Officer Tejas Savant - Morgan Stanley Justin Bowers - Deutsche Bank Max Smock - William Blair Eric Coldwell - Baird Hello all, and welcome to Catalent's First Quarter Fiscal Year 2024 Earnings Call. My name is Lydia and I'll be your operator today. [Operator Instructions]. I'll now hand you over to your host Paul Surdez ...